PDL BIOPHARMA, INC.

(PDLI)
 SummaryChartsNewsCompany 
Company
PDL BioPharma, Inc. has a portfolio of income generating assets based on alternative financings. These alternative financings fall into one of three categories: royalty monetization, debt structures and hybrids of the two. The Company's investments are typically in assets with strong intellectual property protection and are commercial stage or soon-to-be approved. The counterparties in these transactions can be... 
More about the company
All news about PDL BIOPHARMA, INC.
2021Tranche Update on PDL BioPharma, Inc.'s Equity Buyback Plan announced on December 9, 20..
CI
2021PDL BIOPHARMA : Enters into $51.4 Million Capital Provision Agreement with Epps Investment..
AQ
2021PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from S&P TMI Index
CI
2021PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from S&P Global BMI Index
CI
2021PDL BIOPHARMA, INC.(NASDAQGM : PDLI) dropped from NASDAQ Biotechnology Index
CI
2020PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from Russell Microcap Index
CI
2020PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from Russell 3000 Value Index
CI
2020PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from Russell 3000E Index
CI
2020PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from Russell 2000 Defensive Index
CI
2020PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from Russell 2500 Value Index
CI
2020PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from Russell Microcap Value Index
CI
2020PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from Russell 3000E Value Index
CI
2020PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from Russell 2500 Index
CI
2020PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from Russell 2000 Value-Defensive Index
CI
2020PDL BIOPHARMA, INC.(NASDAQGS : PDLI) dropped from Russell 2000 Dynamic Index
CI
More news
News in other languages on PDL BIOPHARMA, INC.
2020PDL BioPharma, Inc. fournit des prévisions de revenus pour 2022
2018Pdl Biopharma, Inc. annonce des résultats consolidés non audités pour le deuxième trime..
2017PDL BioPharma, Inc. présente ses résultats financiers consolidés non audités pour le de..
More news
Chart PDL BIOPHARMA, INC.
Duration : Period :
PDL BioPharma, Inc. Technical Analysis Chart | PDLI | US69329Y1047 | MarketScreener
Managers and Directors
Christopher Lewis Stone CEO, Secretary, Director & General Counsel
Christy Horgan Chief Financial Officer
Elizabeth G. O'Farrell Chairman
John Peter McLaughlin Chief Executive Officer & Director
Dominique P. Monnet Director
Sector and Competitors
1st jan.Capi. (M$)
PDL BIOPHARMA, INC.0.00%282
MODERNA, INC.-48.00%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-28.41%38 232
SEAGEN INC.-13.67%24 569
ICON PUBLIC LIMITED COMPANY-30.17%17 581